Recruitment

Recruitment Status
Unknown status

Inclusion Criterias

Patients on thrice-weekly standard hemodialysis for > 3 months
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients willing to provide written informed consent.
Patients on thrice-weekly standard hemodialysis for > 3 months
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients willing to provide written informed consent.

Exclusion Criterias

Patients with recent major cardiovascular disease during the last 6 months
Patients with active infectious or uncontrolled inflammatory disorders
Patients whose life expectancy < 12 months
...
Patients with recent major cardiovascular disease during the last 6 months
Patients with active infectious or uncontrolled inflammatory disorders
Patients whose life expectancy < 12 months
Patients considered by investigator to have difficulty in participation
Patients with any uncontrolled malignant disease
Patients who are likely to receive kidney transplant within the following 1 year

Summary

Conditions
End-stage Renal Disease
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 20 years and 75 years
Gender
Both males and females

Inclusion Criterias

Patients on thrice-weekly standard hemodialysis for > 3 months
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients willing to provide written informed consent.
Patients on thrice-weekly standard hemodialysis for > 3 months
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients willing to provide written informed consent.

Exclusion Criterias

Patients with recent major cardiovascular disease during the last 6 months
Patients with active infectious or uncontrolled inflammatory disorders
Patients whose life expectancy < 12 months
...
Patients with recent major cardiovascular disease during the last 6 months
Patients with active infectious or uncontrolled inflammatory disorders
Patients whose life expectancy < 12 months
Patients considered by investigator to have difficulty in participation
Patients with any uncontrolled malignant disease
Patients who are likely to receive kidney transplant within the following 1 year

Locations

Seoul
Seoul
Seoul
Seoul
Seoul
...
Seoul
Seoul
Seoul
Seoul
Seoul
Anyang, Gyeonggi-do

Tracking Information

NCT #
NCT02092194
Collaborators
Boryung Pharmaceutical Co., Ltd
Investigators
Study Director: Won-Yong Cho, MD Korea University